As its popularity continues to grow, the secondaries market is seeing increased levels of innovation, competition and regulatory scrutiny, say Gibson Dunn’s Shukie Grossman, Sean McFarlane and Kate Timmerman.
An abundance of deal opportunity and shortage of competition mean that mid-market GP-leds are the place to be, say New 2ND Capital partners Clay Cole and Evert Vink.
After a strong year for LP-led secondaries sales, buyers are shifting their attention to GP-led transactions once again, say Ropes & Gray’s Isabel Dische, Debra Lussier and Paul Van Houten.
Despite a tough fundraising climate, 100 new funds were launched last year by first-time managers, topping the peak set in 2021, says Colleen Fay, a tax partner at Withum.
The highly recurring revenue profile of our businesses and the customized capital structures that we create provide downside protection but maintain upside potential similar to more traditional private equity, says Thayer Street Partners’ Josh Koplewicz
Taxes have the ability to deliver what many allocators view to be the holy grail – uncorrelated returns – says Andy Lee, founder and chief investment officer, Parallaxes Capital.
The key to successful automation is in relying on, and integrating, the people that make manufacturing processes work, according to John Dotson, managing director of operations at MiddleGround Capital.
The last 12 months have seen more ups and downs in the secondaries market than ever before. With GPs and LPs chasing liquidity against an uncertain macro backdrop, activity looks set to unlock in 2024, says our panel of industry veterans.
Sophisticated impact measurement and management is a core imperative, not a side hustle, say Kelly McCarthy and Jon Samuels of Vistria Group.
Innovative strategies from the private sector are required to deliver strong health outcomes for patients across socio-demographics.